A naukri.com initiative
Bioengineer
1w
55
Image Credit: Bioengineer
Insilico Medicine and Partner Unveil Potent WDR5-MYC Interaction Inhibitors Discovered via Generative AI Platform
- Insilico Medicine and Huadong Medicine Company have unveiled potent small-molecule inhibitors targeting the WDR5-MYC protein–protein interaction, a breakthrough enabled by generative AI and physics-driven modeling.
- MYC, a key oncogenic driver in human cancers, historically deemed 'undruggable,' operates through protein–protein interactions like WDR5-MYC, rendering it a challenging drug target.
- By leveraging Insilico's generative AI platform, Chemistry42, novel compounds were designed to disrupt the MYC-WDR5 complex, with compounds 8 and 9 showcasing notable inhibitory potency improvements.
- Further optimization using physics-based modeling led to the development of lead compound 9c-1, demonstrating a significant 35-fold increase in inhibitory activity, highlighting its potential in cancer therapy.
- The success of this AI-driven approach signifies a paradigm shift in drug discovery by efficiently targeting traditionally 'undruggable' proteins, such as MYC, through precise small-molecule design.
- Insilico Medicine's innovative integration of AI and molecular modeling accelerates drug discovery timelines, optimizing lead identification and compound generation for complex targets like PPIs.
- The WDR5-MYC inhibitors represent a groundbreaking strategy to disrupt oncogenic pathways through protein interaction modulation, offering new therapeutic avenues for challenging targets in oncology.
- The study's translational potential lies in advancing lead compound 9c-1 for preclinical evaluations in cancer models, with implications for treating MYC-driven malignancies across various cancer types.
- This collaborative research exemplifies the transformative impact of AI-driven generative chemistry and physics-based modeling in uncovering novel therapeutic agents, revolutionizing drug discovery methodologies.
- The successful application of AI technologies in identifying small-molecule inhibitors for the WDR5-MYC interaction underscores the promise of rational PPI drug design and expands the landscape of therapeutic interventions in oncology and beyond.
- Insilico Medicine's leadership in AI applications for drug design, highlighted by the development of novel WDR5 inhibitors, showcases the potential of AI-driven approaches in creating next-generation medicines with enhanced efficacy and specificity.
Read Full Article
3 Likes
For uninterrupted reading, download the app